Design Therapeutics develops GeneTAC small molecule drug candidates for inherited diseases caused by repeated gene sequences. DSGN reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 2 | Wells Fargo | Initiated | Buy |
Seasonality
How DSGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in DSGN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DSGN is in one of them and how their past DSGN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DSGN in an article yet. Here's the latest on the wider market.
About Design Therapeutics
Design Therapeutics is a biopharmaceutical company based in Carlsbad, California, that researches and develops GeneTAC molecules, a type of small molecule. These molecules are designed to target repeated DNA sequences that cause certain inherited diseases, and to adjust how genes are expressed in affected cells. The company's lead candidates are aimed at Friedreich ataxia, Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1. Its candidates are still in development and are intended for patients with these inherited conditions.
- Headquarters
- Carlsbad, CA